Product Images Asenapine

Not available.*

The text is not-readable.*

This text provides information on the potential changes in pharmacokinetic parameters such as Cmax and AUC when certain drugs are co-administered with inhibitors of specific cytochrome P450 enzymes. The drugs mentioned include fluvoxamine, imipramine, paroxetine, carbamazepine, and valproate, among others. The text also reports a specific example of how fluvoxamine can affect the exposure of asenapine.*

This text provides information about the effect of certain drugs on the metabolism of other drugs by different enzymes. It includes data on the change in peak plasma concentration (Cmax) and area under the curve (AUC) for substrate/inhibitor drugs of CYP1A2/2C19/3A4 and CYP2C19/2D6 enzymes. There is also information on the inhibitory effect of Paroxetine on its own metabolism and the weak inhibitory effect of Asenapine on CYP206, based on studies with healthy subjects. Additionally, it is reported that coadministration of Asenapine and Imipramine did not affect the plasma concentrations of the metabolite Desipramine.*

This figure presents the effect of intrinsic factors on the pharmacokinetics of Asenapine. It shows the population description, including renal and hepatic impairment, smoking status, and ethnicity. The figure provides information on Cmax and AUC, as well as fold change and 90% CI. The data for renal and hepatic impairment are relative to subjects with normal function, and the data for smokers are relative to non-smokers. The Japanese data is relative to Caucasians.*

The text "Tablet Pack" suggests that there might be a packaging designed specifically for tablets - this could refer to either electronic tablets or tablet medication. The mention of the "Thumb Button" is too vague to provide any useful context about what the button is for.*